Results 201 to 210 of about 76,021 (334)

In Utero Exposure to Di-(2-Ethylhexyl) Phthalate Decreases Mineralocorticoid Receptor Expression in the Adult Testis [PDF]

, 2009
Daniel B. Martinez–Arguelles, Martine Culty, B. R. Zirkin, V. Papadopoulos   +3 more
openalex   +1 more source

Validation of grizzly bear hair hormone profiles as a tool to monitor population demographics

The Journal of Wildlife Management, Volume 90, Issue 2, February 2026.
We measured 16 steroid and thyroid hormone concentrations in grizzly bear hair to predict sex, age class, and reproductive status. Models were highly accurate when predicting sex and age class and showed promise for assessing reproductive status. Results illustrate the potential for hair hormone profiles as non‐invasive population monitoring tools ...
Abbey E. Wilson, Cameron J. R. McClelland, Sarah A. Michaud, Jun Han, Gordon Stenhouse, David R. Goodlett, Kristenn Magnusson, Karen Graham, Hugo Fernández‐Bellon, David M. Janz, Darío Fernández‐Bellon   +10 more
wiley   +1 more source

Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review. [PDF]

Cureus
George V, Pillai MH, Jacob V, Mp R, Vasant A, Adnan H.   +5 more
europepmc   +1 more source

Recurrent haemorrhage, due to vitamin K‐dependent coagulopathy, as the primary presenting complaint in a dog with naturally occurring hypoadrenocorticism

Veterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 5‐year‐old male neutered standard poodle, presented with recurrent gingival margin haemorrhage and associated prolongations in prothrombin time and activated partial thromboplastin time, with repeatable demonstration of clinical (bleeding) and laboratory (prothrombin time, activated partial thromboplastin time) resolution with, and relapse ...
Jenny Reeve, Aiden Pang
wiley   +1 more source

Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial. [PDF]

BMJ Open
Merabtine A, Leung AA, Kline GA, Dubrofsky L, Hundemer GL, Goupil R.   +5 more
europepmc   +1 more source

Antagonism of Kinin Receptors B1 and B2 Attenuates Folic Acid‐Induced Tubulointerstitial Fibrosis in Mice

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 2, February 2026.
ABSTRACT Chronic kidney disease (CKD) remains a significant global health burden despite recent advances in pharmacotherapy, including sodium‐glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists. Renal fibrosis, a central pathological hallmark of CKD progression, is mediated by persistent inflammation and macrophage ...
Gabriel Rufino Estrela, Alexandre Budu, Juliene Silva, Raisa Brito, Frederick Wasinski, Jonatan Barrera‐Chimal, Ronaldo Carvalho Araujo   +6 more
wiley   +1 more source

A Retrospective Study on the Impact of Primary Aldosteronism in Pregnancy (H.A.P.P.I. Study Group)

Clinical Endocrinology, Volume 104, Issue 2, Page 113-122, February 2026.
ABSTRACT Objective Primary aldosteronism (PA) is a common cause of hypertension in young women. However, there is a paucity of data regarding its impact during pregnancy. The primary objective of this study was to describe the occurrence of hypertensive disorders of pregnancy (HDP) in PA.
Diana Oprea, Frédérique Lefrançois, Matthieu St‐Jean, Anne‐Marie Côté, Marie‐Ève Roy‐Lacroix, Mandy Malick, Pierre‐Luc Mallet, Nadine Sauvé   +7 more
wiley   +1 more source

Endocrine consequences of antifungal therapy: A missed entity. [PDF]

World J Clin Cases
Thakkar S, Kantroo V, Nagendra L, Dutta D, Kamrul-Hasan ABM, Kalra S, Bhattacharya S.   +6 more
europepmc   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis. [PDF]

BMC Ophthalmol
Park JY, Jang Y, Hahn S.
europepmc   +1 more source